"Neurofibromin 1" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A protein found most abundantly in the nervous system. Defects or deficiencies in this protein are associated with NEUROFIBROMATOSIS 1, Watson syndrome, and LEOPARD syndrome. Mutations in the gene (GENE, NEUROFIBROMATOSIS 1) affect two known functions: regulation of ras-GTPase and tumor suppression.
| Descriptor ID |
D025542
|
| MeSH Number(s) |
D12.644.360.325.150.500.460 D12.776.476.325.150.500.460 D12.776.624.776.610
|
| Concept/Terms |
Neurofibromin 1- Neurofibromin 1
- Neurofibromatosis Type 1 Protein
- NF1-GAP-Related Protein
- NF1 GAP Related Protein
- NF-1 Protein
- NF 1 Protein
- NF1 GRP
- NF1 Protein
- Neurofibromin
- Neurofibromatosis Type 1 Gene Product
|
Below are MeSH descriptors whose meaning is more general than "Neurofibromin 1".
Below are MeSH descriptors whose meaning is more specific than "Neurofibromin 1".
This graph shows the total number of publications written about "Neurofibromin 1" by people in this website by year, and whether "Neurofibromin 1" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 0 | 1 | 1 |
| 2006 | 1 | 0 | 1 |
| 2010 | 1 | 0 | 1 |
| 2011 | 1 | 0 | 1 |
| 2012 | 1 | 0 | 1 |
| 2013 | 1 | 0 | 1 |
| 2014 | 2 | 2 | 4 |
| 2015 | 2 | 0 | 2 |
| 2016 | 1 | 0 | 1 |
| 2017 | 1 | 0 | 1 |
| 2018 | 1 | 2 | 3 |
| 2019 | 3 | 1 | 4 |
| 2020 | 1 | 1 | 2 |
| 2023 | 0 | 1 | 1 |
| 2025 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Neurofibromin 1" by people in Profiles.
-
NF1-depleted ER+ breast cancers are differentially sensitive to CDK4/6 inhibitors. Sci Transl Med. 2025 Aug 27; 17(813):eadq5492.
-
Proteogenomic Approaches for the Identification of NF1/Neurofibromin-depleted Estrogen Receptor-positive Breast Cancers for Targeted Treatment. Cancer Res Commun. 2023 07; 3(7):1366-1377.
-
Integrated Molecular and Clinical Analysis of 1,000 Pediatric Low-Grade Gliomas. Cancer Cell. 2020 04 13; 37(4):569-583.e5.
-
Neurofibromin Is an Estrogen Receptor-a Transcriptional Co-repressor in Breast Cancer. Cancer Cell. 2020 03 16; 37(3):387-402.e7.
-
Phenotype categorization of neurofibromatosis type I and correlation to NF1 mutation types. J Hum Genet. 2020 Jan; 65(2):79-89.
-
Genomic Profiling of Childhood Tumor Patient-Derived Xenograft Models to Enable Rational Clinical Trial Design. Cell Rep. 2019 11 05; 29(6):1675-1689.e9.
-
Clinical spectrum of individuals with pathogenic NF1 missense variants affecting p.Met1149, p.Arg1276, and p.Lys1423: genotype-phenotype study in neurofibromatosis type 1. Hum Mutat. 2020 01; 41(1):299-315.
-
Fetal cardiomyopathy in neurofibromatosis type I: Novel phenotype and review of the literature. Am J Med Genet A. 2019 06; 179(6):1042-1046.
-
Expanding the clinical phenotype of individuals with a 3-bp in-frame deletion of the NF1 gene (c.2970_2972del): an update of genotype-phenotype correlation. Genet Med. 2019 04; 21(4):867-876.
-
The prognostic effects of somatic mutations in ER-positive breast cancer. Nat Commun. 2018 09 04; 9(1):3476.